StemCell Therapy

Spero Therapeutics Inc. (NASDAQ:SPRO) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), both competing one another are Biotechnology companies. We will compare their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Valuation & Earnings

Table 1 showcases the gross revenue, earnings per share and valuation of Spero Therapeutics Inc. and Brainstorm Cell Therapeutics Inc.

Profitability

Table 2 has Spero Therapeutics Inc. and Brainstorm Cell Therapeutics Inc.s return on assets, return on equity and net margins.

Liquidity

The Current Ratio and Quick Ratio of Spero Therapeutics Inc. are 17.5 and 17.5 respectively. Its competitor Brainstorm Cell Therapeutics Inc.s Current Ratio is 1 and its Quick Ratio is 1. Spero Therapeutics Inc. can pay off short and long-term obligations better than Brainstorm Cell Therapeutics Inc.

Analyst Recommendations

Spero Therapeutics Inc. and Brainstorm Cell Therapeutics Inc. Ratings and Recommendations are available on the next table.

Spero Therapeutics Inc.s average target price is $28, while its potential upside is 166.67%. Brainstorm Cell Therapeutics Inc. on the other hand boasts of a $9 average target price and a 134.99% potential upside. The results from earlier shows that analysts opinion suggest that Spero Therapeutics Inc. seems more appealing than Brainstorm Cell Therapeutics Inc.

Insider & Institutional Ownership

Spero Therapeutics Inc. and Brainstorm Cell Therapeutics Inc. has shares owned by institutional investors as follows: 53.1% and 11.4%. Insiders owned roughly 23.71% of Spero Therapeutics Inc.s shares. Insiders Competitively, owned 0.6% of Brainstorm Cell Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Spero Therapeutics Inc. was more bullish than Brainstorm Cell Therapeutics Inc.

Summary

Spero Therapeutics Inc. beats Brainstorm Cell Therapeutics Inc. on 6 of the 11 factors.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

The rest is here:
Contrasting of Spero Therapeutics Inc. (SPRO) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - FinanceMercury

This entry was posted on November 6, 2019 at 8:43 am and is filed under Stem Cell Negative. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |